Hologic (HOLX)
(Delayed Data from NSDQ)
$74.51 USD
-0.27 (-0.36%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $74.49 -0.02 (-0.03%) 4:42 PM ET
2-Buy of 5 2
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.51 USD
-0.27 (-0.36%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $74.49 -0.02 (-0.03%) 4:42 PM ET
2-Buy of 5 2
B Value D Growth C Momentum C VGM
Zacks News
Baxter's (BAX) New Launch to Support Complex Critical Care Needs
by Zacks Equity Research
Baxter's (BAX) Progressa+ bed for the ICU is expected to enhance workflow and reduce strain on nursing resources.
PacBio (PACB) Gets New Order for Revio System From Bioscientia
by Zacks Equity Research
PacBio (PACB) receives new order for its Revio system from Bioscientia that will boost the latter's services. Here's how Revio can help Bioscientia improve diagnosis and treatment for monogenic disorders.
Thermo Fisher's (TMO) New Launch to Advance Cancer Therapies
by Zacks Equity Research
Thermo Fisher's (TMO) Gibco OncoPro Tumoroid Culture Medium Kit is intended to increase researchers' access to sophisticated cancer models.
OPKO Health's (OPK) NGENLA Approved by FDA for GHD Treatment
by Zacks Equity Research
The latest approval for OPKO Health's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.
Walgreens (WBA) to Advance Diabetes Care at FFL Conference
by Zacks Equity Research
Walgreens (WBA) will sponsor Children with Diabetes' FFL event to make a difference in the lives of the 122 million individuals afflicted by diabetes and pre-diabetes.
Hologic (HOLX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $80.24, moving -0.72% from the previous trading session.
Three Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) due to the performance of its oncology business and product launches.
Amedisys (AMED) to Advance Value-Based Care With Optum Merger
by Zacks Equity Research
Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) backed by the acquisition of Oak Street Health, which broadens its value-based primary care platform.
Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Stock
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
McKesson's (MCK) Latest Launch to Give Access to OTC Products
by Zacks Equity Research
McKesson's (MCK) latest launch is expected to meet the evolving needs and growing demand for quality OTC private-label health and wellness products.
Three Reasons to Add Masimo (MASI) Stock to Your Portfolio
by Zacks Equity Research
Masimo's (MASI) solid product suite raises optimism about the stock.
Dexcom (DXCM) to Launch New Product in 2024, Ups Long-Term View
by Zacks Equity Research
Dexcom (DXCM) announces encouraging developments in 2024, including faster coverage for its products by private payers and new product launch for diabetic patients not on insulin.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in Diabetes business and upbeat guidance.
Inspire Medical (INSP) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Inspire Medical's (INSP) global presence.
Masimo's (MASI) W1 to Boost Virtual Care in Preoperative Patients
by Zacks Equity Research
Masimo's (MASI) W1 advanced health-tracking watch is expected to provide better insights into pre-operative patients' heart rate variability data and improve pre-habilitation.
Envista (NVST) Gains From New Acquisitions Amid FX Woes
by Zacks Equity Research
Envista's (NVST) implant businesses in Europe perform well on the back of disciplined commercial execution.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) due to the performance of its dental business.
Abbott (ABT) FreeStyle Libre 2 Gets Reimbursement in France
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre increased reimbursement makes it possible for more people in France with diabetes to use the recent CGM technology.
Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its product innovation aiding growth.
Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure
by Zacks Equity Research
Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.
Hologic (HOLX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Hologic (HOLX) closed at $81.49 in the latest trading session, marking a +0.07% move from the prior day.
Quest Diagnostics' (DGX) New Buyout Expands Cancer Portfolio
by Zacks Equity Research
Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.
Masimo's (MASI) Launch to Serve the Personalized Hearables Market
by Zacks Equity Research
Masimo's (MASI) new product offerings are expected to enable it to expand its footprint in the personalized hearables market.